Equillium (EQ) Times Interest Earned (2018 - 2026)
Equillium (EQ) posted quarterly Times Interest Earned of -$0.53 for Q1 2026, up 99.43% year-over-year from -$0.26 in Q1 2025, and up 99.48% quarter-over-quarter from -$101.59 in Q4 2025.
Equillium (EQ) Times Interest Earned (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Times Interest Earned for 9 consecutive years, with -$0.53 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 99.43% year-over-year to -$0.53; the TTM figure through Mar 2026 stood at -$1.91 (up 87.91% YoY), while the FY2025 annual figure was -$0.43, down 166.12% from the prior year.
- Times Interest Earned climbed to -$0.53 in Q1 2026 per EQ's latest filing, from -$101.59 in the prior quarter.
- Across five years, Times Interest Earned topped out at $31.42 in Q4 2022 and bottomed at -$101.59 in Q4 2025.
- Historically, Times Interest Earned has averaged -$25.14 across 5 years, with a median of -$12.37 in 2023.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 108.77% — and 2025, when it sank 44813.45%.
- Equillium's Times Interest Earned stood at $31.42 in 2022, then tumbled by 122.39% to -$7.03 in 2023, then sank by 443.09% to -$38.2 in 2024, then sank by 165.98% to -$101.59 in 2025, then jumped by 99.48% to -$0.53 in 2026.
- Business Quant data shows EQ's Times Interest Earned at -$0.53 in Q1 2026, -$101.59 in Q4 2025, and -$1.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.18 |
| Mar 31, 2026 | -0.53 |
| Dec 31, 2025 | -101.59 |
| Sep 30, 2025 | -1.04 |
| Mar 31, 2025 | -92.40 |
| Dec 31, 2024 | -38.20 |
| Sep 30, 2024 | -1.21 |
| Jun 30, 2024 | -1.85 |
| Mar 31, 2024 | -0.21 |
| Dec 31, 2023 | -7.03 |
| Sep 30, 2023 | -21.44 |
| Jun 30, 2023 | -3.13 |
| Mar 31, 2023 | -17.71 |
| Dec 31, 2022 | 31.42 |
| Sep 30, 2022 | -49.58 |
| Jun 30, 2022 | -47.38 |
| Mar 31, 2022 | -50.31 |
| Dec 31, 2021 | -358.17 |
| Sep 30, 2021 | -1.09 |
| Jun 30, 2021 | -1.50 |